Olink Target 96 Development

Casting a broader net to further explore the complexity of the human proteome

Complementing and expanding on our previous portfolio of disease area-focused biomarker panels, our exploratory panels offers scientists the chance to cast a wider net in the quest to identify new biomarkers and relevant protein signatures, offering many new assays focused on important biological processes with wide-ranging clinical relevance.

The Development panel offers simultaneous analysis of 92 protein biomarkers using just 1 µL of biological sample, and all assays are subject to Olink’s strict technical validation and QC control procedures. The selection of protein biomarker assays is designed to provide the optimal dynamic range, as well as to focus on proteins with relevance for developmental processes. Categorization of the proteins included in the panel was carried out via referral to widely used public-access bioinformatic databases, including Uniprot, Human Protein Atlas, Gene Ontology (GO) and DisGeNET. The assays in this panel include proteins involved in key biological processes such as cell migration & motility, extracellular matrix organization and neurogenesis.

Please Note: The DEVELOPMENT panel uses a 1:100 dilution of sample, whereas our technical validation assays are performed in vitro using recombinant analytes . Technical validation data reported on the biomarker pages below, and in the data validation document for this panel  are based on these in vitro assays. A multiplication factor of 100 should therefore be taken into consideration when comparing the addressable biological concentration to the in vitro validation data. (Sample dilution guidelines can be found in the User Manual.)

Panel version

Please note that the protein assay details shown below apply to the version of the panel with article number 95352, released on October 1, 2020 – see update details here

Protein assays

An alphabetical list of the 92 proteins with links to the individual biomarker pages containing additional information and assay validation data can be found at the bottom of this page.

An overview of how the 92 biomarker assays in the panel are classified according to Biological Process, Disease Area, Tissue Expression and Protein Class (based on widely used public-access bioinformatic databases, including Uniprot, Human Protein Atlas, Gene Ontology (GO) and DisGeNET) can be seen in the charts below. These charts are interactive: click on a chart-bar or pie-segment to see the list of biomarkers in that classification. Each item in the list links to the detailed biomarker page with validation data. Please note that these classifications are intended for general guidance only and while correct at the time of publication, they are not updated in real-time and you are advised to always check the source databases in order to see the latest updates regarding the information for specific proteins.

Biological Process

Disease Area

Tissue Expression

Protein Class

A comprehensive list of all protein biomarkers that can be measured using the currently available biomarker panels can be seen on the biomarker library page.

Note: A printable list of the biomarker assays available in this panel, as well as a full data validation document, can be downloaded from our Document download center >>

If you prefer not to run the assay yourself, let our experts here at Olink do this for you via our Analysis Service.

The biomarker pages linked to below include calibrator curves that show the performance of each assay with the estimated sensitivity and dynamic range parameters indicated. These curves are generated during the assay validation process using recombinant antigens, with data presented as Normalized Protein eXpression (NPX) values plotted against protein concentration (in pg/mL). Please note that when analyzing biological samples the data generated will be given in the form of relative quantification (NPX values) and cannot be converted to absolute protein concentrations. For more info about NPX measurements, please view the FAQ.